Nektar Therapeutics (#NKTR) announced publication in The Lancet of positive Phase 2b REZOLVE-AD 16-week induction results for rezpegaldesleukin in moderate-to-severe atopic dermatitis. 🔹 Key Highlights 🧪 The study met all primary and key secondary endpoints. 📊 Results included EASI-75, EASI-90, Itch NRS, vIGA-AD, and BSA. 💊 The 24 µg/kg every-two-weeks (q2w) dose delivered the positive results. 🔬 The trial was a large, placebo-controlled study supporting T-reg modulation as a potential mechanism for chronic inflammatory disease. 🚀 Results support continued development in the Phase 3 ZENITH AD program. 💡 Why It Matters The positive Phase 2b results strengthen the clinical case for rezpegaldesleukin and provide support for its continued advancement into Phase 3 development for atopic dermatitis. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified